{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:14:06Z","timestamp":1790021646598,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1053\/j.seminhematol.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T02:16:04Z","timestamp":1688696164000},"page":"226-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana"],"prefix":"10.1053","volume":"60","author":[{"given":"Christine","family":"Nyonator","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emefa","family":"Amoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etta Forson","family":"Addo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Mukanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine Kwabena","family":"Asubonteng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwaku","family":"Ohene-Frempong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Michael","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon Fiifi","family":"Ofori-Acquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2023.06.001_bib0001","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2352-3026(19)30111-5","article-title":"Sickle cell disease: a new era","volume":"6","author":"Simpson","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0002","unstructured":"United Nations, General assembly, recognition of sickle cell anaemia as a public health problem, A\/RES\/63\/237, sixty-third session (2008). https:\/\/digitallibrary.un.org\/record\/644334\/files\/A_RES_63_237-EN.pdf, [Accessed on June 15, 2023]."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0003","series-title":"Engaging the private sector and developing partnerships to advance health a","year":"2017"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0004","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.ymthe.2021.05.024","article-title":"Collaborative science to advance gene therapies in resource-limited parts of the world","volume":"29","author":"McCune","year":"2021","journal-title":"Mol Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/phar.2792","article-title":"Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: a summary of the evidence, opportunities, and challenges","volume":"43","author":"Dexter","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/jlac.18691500212","article-title":"Ueber den Hydroxylharnstoff","volume":"150","author":"Dresler","year":"1869","journal-title":"Justus Liebigs Ann Chemie"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0007","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood.V3.4.465.465","article-title":"A study of sickling of young erythrocytes in sickle cell anemia","volume":"3","author":"Watson","year":"1948","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(60)90003-6","article-title":"Hereditary persistence of fetal hemoglobin: a family study","volume":"29","author":"Herman","year":"1960","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0009","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia","volume":"74","author":"Platt","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0011","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0012","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2020-038685","article-title":"Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability","volume":"10","author":"Ryan","year":"2020","journal-title":"BMJ Open"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMe1814706","article-title":"Hydroxyurea\u2014An essential medicine for sickle cell disease in Africa","volume":"380","author":"Luzzatto","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0015","doi-asserted-by":"crossref","unstructured":"World Health Organization model list of essential medicines (22nd list). 2021. https:\/\/www.who.int\/publications\/i\/item\/eml-20 (accessed April 7, 2023).","DOI":"10.1530\/ey.19.13.1"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0016","unstructured":"Novartis in society integrated report. 2022 https:\/\/www.novartis.com\/sites\/novartis_com\/files\/novartis-integrated-report-2022.pdf, [Accessed on June 15, 2023]."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0017","unstructured":"Mobilizing partnerships to impact sickle cell disease in Africa: Report from a Roundtable Discussion held in parallel with the 2018 World Health Assembly, May 22nd, Geneva, Switzerland. Sickle Cell Foundation of Ghana and Novartis."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0018","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","article-title":"Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia","volume":"130","author":"Opoka","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0020","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","article-title":"Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa","volume":"382","author":"John","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0140-6736(20)30293-2","article-title":"Ghana takes on sickle-cell disease","volume":"395","author":"Adepoju","year":"2020","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2023.06.001_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.HS9.0000821484.39112.40","article-title":"S129: Implementation of hydroxyurea therapy for sickle cell disease on a large scale in Ghana","volume":"6","author":"Ohene-Frempong","year":"2022","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0023","unstructured":"Ministry of Health, Republic of Ghana. Government of Ghana makes hydroxyurea available to people with sickle cell disease through first of its kind public-private partnership with global medicines company Novartis. 2019. https:\/\/www.moh.gov.gh\/wp-content\/uploads\/2019\/11\/Novartis-media-release-Ghana-MOU-November-2019-v7.pdf (accessed April 7, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0024","unstructured":"Ministry of Health, Republic of Ghana. MOH & Novartis sign MOU on treatment of sickle cell disease at World Economic Forum, 2019. https:\/\/www.moh.gov.gh\/moh-novartis-foundation-signs-mou-on-treatment-of-sickle-cell-disease-at-world-economic-forum-2019\/(accessed April 7, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0025","unstructured":"Bawumia launches first public-private sickle cell partnership in Ghana and Africa. https:\/\/www.ghanaweb.com\/GhanaHomePage\/NewsArchive\/Bawumia-launches-first-Public-Private-sickle-cell-partnership-in-Ghana-and-Africa-797196 (accessed April 9, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0026","unstructured":"World Health Organization. Guidelines for Medicine Donations. Revised 2010. Geneva, Switzerland."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0027","series-title":"American Society of Tropical Medicine and Hygiene Annual Meeting","article-title":"Multi-sectoral collaboration to improve access to medicines for sickle cell disease in sub-Saharan Africa [Abstract]","author":"Hammond-Addo","year":"2021"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0028","unstructured":"Health insurance scheme to rollout free cancer and sickle cell treatment for children. https:\/\/www.ghanaweb.com\/GhanaHomePage\/NewsArchive\/Health-Insurance-Scheme-to-rollout-free-cancer-and-sickle-cell-treatment-for-children-1567832 (accessed April 7, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0029","unstructured":"Ghana National Health Insurance Authority. https:\/\/www.nhis.gov.gh\/about (accessed April 9, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0030","unstructured":"\u2018Optimized for the underserved\u2019: a new diagnostic test built for low-income settings. https:\/\/www.devex.com\/news\/optimized-for-the-underserved-a-new-diagnostic-test-built-for-low-income-settings-97456 (accessed June 16, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0031","unstructured":"PerkinElmer makes donation to expand SCD screening in Ghana. https:\/\/sicklecellanemianews.com\/news\/perkinelmer-donation-newborn-sickle-cell-screening-ghana (accessed June 16, 2023)."},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0032","author":"Frost","year":"2008"},{"key":"10.1053\/j.seminhematol.2023.06.001_bib0033","unstructured":"African health ministers launch drive to curb sickle cell disease toll. https:\/\/www.afro.who.int\/news\/african-health-ministers-launch-drive-curb-sickle-cell-disease-toll (accessed May 5, 2023)."}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:57Z","timestamp":1758522537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0037196323000483"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.06.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}